ROJA RANI BUDHA
@hkcp.edu.in
Assistant Professor, Department of Pharmacology
H. K. College of Pharmacy
Ph.D from Sri Padmavati Mahila Visvavidyalayam;
M.Pharm Pharmacology from Annamalai University;
B.Pharm from Acharya Nagarjuna University
EDUCATION
M.Pharm, Ph.D.
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmacology, Toxicology and Pharmaceutics, General Pharmacology, Toxicology and Pharmaceutics, Pharmacology, Pharmaceutical Science
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Vutti Nagendra Babu, Gudhanti S. N. Koteswara Rao, Roja Rani Budha, Rajasekhar Reddy Alavala, Prasanna Kumar Desu, Govada Kishore Babu, and Arja Durga Prasad
Open Science Publishers LLP
The study aims to formulate solid lipid nanoparticles (SLNPs) of the poorly bioavailable drug α-mangostin by central composite design and evaluate their in-vitro drug characteristics. The contribution of ingredients to the physicochemical characteristics of formulated SLNPs was investigated and further utilized to optimize the final formulation. For the formulation of SLNPs, hot melt homogenization method was used followed by a ultrasonication approach. The solid lipids used in the formulation include stearic acid and Precirol ATO5; the surfactant was Poloxamer 407, and the co-surfactant was sodium taurocholate to provide the negative charge. The optimized formulation’s mean particle size, entrapment efficiency, zeta potential, and drug loading were 173.6 nm, 72.42%, −43.3 mV, and 20.46%, respectively. X-ray diffractometry confirms the amorphous nature of SLNPs. Scanning electron microscopy analysis showed spherical morphology and a particle size range between 145 and 218 nm. Differential scanning calorimetry and Fourier transform infrared studies confirmed the absence of drug-excipient interactions. According to the findings, the optimum surfactant and lipid combination produced high-quality SLNPs with stable release properties for at least 6 months at room and refrigerator temperatures. The obtained results encourage that SLNPs can be used as oral drug delivery carriers for α-Mangostin, because of their exceptional properties.
GSN Koteswara Rao, Rajasekhar Reddy Alavala, Praveen Sivadasu, Roja Rani Budha, and Khushwant S. Yadav
Elsevier
Nagendra Babu VUTTI, SN Koteswara Rao GUDHANTI, Rajasekhar Reddy ALAVALA, Prasanna Kumar DESU, Roja Rani BUDHA, Kishore Babu GOVADA, Durga Prasad ARJA, and Nagendra CH
ASOS Yayinevi
Roja Rani Budha, Santhrani Thaakur, GSN Koteswara Rao, Lavanya Yaidikar, M. Sathish Kumar, and Ravi Manne
A and V Publications
Diabetes is the most prevailing health disorder with high mortality rate and showing increased health costs across the globe. World Health Organization has claimed that lifestyle changes are one of the major causes of diabetes in this modern living. Gliclazide is an oral antidiabetic drug that is taken by majority of patients suffering with type-2 diabetes. With the increased awareness of nutraceuticals in health care management, many patients are consuming them. Hence, in the present investigation it is sought to determine the pharmacokinetic and pharmacodynamic interactions of gliclazide with eugenol in diabetic induced rabbits. Streptozotocin was used for inducing diabetes in healthy rabbits. Four different groups, each with 6 rabbits, are taken in the study. Group A is diabetic control, Group B is treated with gliclazide alone, Group C is treated with eugenol alone and Group D is treated with combination of gliclazide and eugenol. The results clearly indicated that there is an advantage in both pharmacokinetic and pharmacodynamic parameters with combination therapy of gliclazide and eugenol in diabetic rabbits.
Hibah M. Aldawsari, N. Raghavendra Naveen, Nabil A. Alhakamy, Prakash S. Goudanavar, GSN Koteswara Rao, Roja Rani Budha, Anroop B. Nair, and Shaimaa M. Badr-Eldin
Informa UK Limited
Abstract Pulsatile drug delivery systems have drawn attention in contemporary research for designing chronotherapeutic systems. The current work aims to design pulsatile ketorolac tromethamine tablets using compression coating for delayed delivery with a lag time suitable for the treatment of morning stiffness in arthritis. Rapidly disintegrating core tablets of ketorolac tromethamine were formulated using super-disintegrants, and the optimized formulation was compression using PEO WSR coagulant and Eudragit RLPO for delaying the release. The central composite design and response surface methodology were employed to optimize the formulation and process parameters namely PEO WSR Coagulant (X1), Eudragit RLPO (X2), and Hardness (X3). The dependent variables optimized were lag time and time required for 95% drug release. Analysis using response surface graphs and mathematical modeling of the results allowed identifying and quantifying the formulation variables active on the selected responses. A polynomial equation fitted to the data was used to predict the composition with optimum responses. Compression-coated pulsatile tablets’ optimized composition exhibited a lag time of 9 h and released 95% of the ketorolac tromethamine in 17.42 h. Validation of the mathematical model assured the reliability of QBD in formulation design. In vivo X-ray imaging and pharmacokinetic studies established a strong relationship between the coated polymers maintaining the desired lag time for delayed delivery of the active to coincide with the chronobiology for enhanced bioavailability at the right time when needed.
B. Y. Kumar, G. Chakravarthi, G.S.N. K. Rao, A. R. Reddy, K. K. Naidu, and K. Umasankar
Indian Pharmaceutical Association - IPA
Taking right medicine at the right time is vital to ensure safety and speedy recovery of the patient. The aim of this study was to conduct a comprehensive review systematic analysis and outcomes of the medication discrepancies which occur as a result of inappropriate prescribing in a hospital setting. A cross sectional study was performed between July 2018 to April 2019 at Star hospitals, South India. A total of 300 prescriptions were collected from different inpatient departments by two practising clinical pharmacists. We used the standard World Health Organization methodology to achieve the study objectives. A feasible sampling technique was used to collect the prescriptions from various departments. Various clinical drug databases like Medscape, Micromedex, and Pub Med were referred. A total of 300 prescriptions were collected and reviewed which comprised 62 % Documentation discrepancies, 19.6 % of omission errors, 10.3 % of prescriptions exceeding the maximum dose, 0.8 % were of prescriptions contained therapeutic duplications. Drugs prescribed out of the formulary also contributed to medication related errors. Mid-level health care practioners were also involved on this study. The study evidenced the potential of inappropriate prescription occurring in the hospital setting ranging from patient admission to discharge. Several factors such as multiple co-morbidities, ploy pharmacy, hassle at the work environment and poor communication among allied health care professionals were found to be the major causes of potential inappropriate prescribing. Execution of efficient strategies will help in controlling the harmful outcomes as a result of irrational prescribing.